---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-006873"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T00:56:26.037469+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Harrow licenses Canadian rights to five ophthalmic products to Apotex; eligible for milestone payments and royalties

## Summary
- Apotex gets exclusive Canadian rights to VERKAZIA and Cationorm PLUS; will pursue approval for VEVYE, IHEEZO, and ZERVIATE.
- Harrow eligible for milestone payments tied to manufacturing, regulatory approval, and commercial milestones plus royalties on net sales.
- Apotex is Canada's largest pharmaceutical company, with a track record in eyecare.
- Deal covers both prescription (VERKAZIA) and OTC (Cationorm PLUS) products, expanding Harrow's reach into Canada.

## SEC filing metadata
- accession: 0001493152-24-006873
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315224006873/0001493152-24-006873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315224006873/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-006873
- JSON: https://secwatch.observer/filing/0001493152-24-006873.json
- Plain text: https://secwatch.observer/filing/0001493152-24-006873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.